04 May

Posted at 16:38h in COVID-19, Risk Management by . .
[wpseo_breadcrumb]

Legal Update Header On Apr. 20, 2021, the Occupational Safety and Health Administration (OSHA) provided guidance for recording COVID-19 vaccination adverse reactions.

The guidance comes in the format of frequently asked questions for adverse reactions under two scenarios: employer-required and voluntary vaccination.

Employer-required Vaccination

According to OSHA’s guidance, employers are required to record adverse reactions to the vaccine if the reactions are:

04 May

Posted at 16:14h in COVID-19, HR and Operations by . .
[wpseo_breadcrumb]

HR Insights Blog Header Employers play a critical role in helping promote and provide accurate information about COVID-19 vaccines.

Employees getting vaccinated can be a driving force for a safe return to work. As employers navigate the legal risks and logistics of return-to-work plans and employee vaccinations, this article explores considerations for increasing employee vaccine acceptance across their organizations.

29 Apr

Posted at 23:13h in COVID-19, Employee Benefits by . .
[wpseo_breadcrumb]

News Brief header In a joint statement, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have recommended lifting a pause on the distribution of the Johnson & Johnson (J&J) COVID-19 vaccine.

On April 13, the agencies recommended a pause on the J&J one-dose vaccine after reports of six cases of a rare and severe type of blood clot in individuals following administration of the vaccine. Reports of adverse events following the use of the J&J vaccine suggested an increased risk of a rare adverse event called thrombosis with thrombocytopenia syndrome (TTS). Nearly all reports of this serious condition, which involves blood clots with low platelets, have been in adult women under the age of 50.

16 Apr

Posted at 17:30h in COVID-19, Risk Management by . .
[wpseo_breadcrumb]

News Brief header In a joint statement, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have called for an immediate halt on the distribution of the Johnson & Johnson (J&J) COVID-19 vaccine.

The CDC’s Advisory Committee on Immunization Practices will meet on Wednesday, April 14, to further review these cases and assess their potential significance. Until that process is complete, the agencies are recommending a pause in the use of the J&J vaccine out of an abundance of caution.